On June 4, Baoji Pharma-B surged 13.37% in regular trading, trading at 24.12 HKD/share, with trading volume of 49.80 million HKD. The stock staged a strong rebound after two consecutive sessions of decline totaling over 10%, during which it touched a 52-week low of 22.90 HKD.

On the news front, the rebound was driven by oversold technical recovery combined with multiple positive catalysts. The company was recently included in the MSCI Global Index, with passive fund rebalancing selling pressure now largely digested following the effective date on May 29. Additionally, China Post Securities initiated coverage with a Buy rating, citing the company entering its commercialization phase with its first product SJ02 approved in August last year and core product KJ017 approved in March this year as China's first approved recombinant human hyaluronidase. The appointment of new Chairman Liu Yanjun has also provided governance stability.

The stock had previously plunged 65% in late April and had been consolidating at depressed levels. With selling pressure from index rebalancing absorbed, the market appears to be entering a confidence recovery phase.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)